BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fetrastobart vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fetrastobart vedotin\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05208762-2168@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20280105
DTEND;VALUE=DATE:20280106
SUMMARY:Fetrastobart vedotin: Phase 1 readout est. (NCT05208762)
DESCRIPTION:Fetrastobart vedotin\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors\nEstimated
  primary completion: 5 January 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fetrastobart-vedotin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05208762
URL:https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07144280-2168@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:Fetrastobart vedotin: Phase 3 readout est. (NCT07144280)
DESCRIPTION:Fetrastobart vedotin\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL
 1V Versus Docetaxel in Adult Participants With Previously-Treated Programm
 ed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: 10 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07144280
URL:https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227298-2168@assetmemo.bio
DTSTAMP:20261121T010442Z
DTSTART;VALUE=DATE:20290308
DTEND;VALUE=DATE:20290309
SUMMARY:Fetrastobart vedotin: Phase 1/2 readout est. (NCT07227298)
DESCRIPTION:Fetrastobart vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Symbiotic-Lung-20: A Study to Learn About the Study Medicine Calle
 d PF-08634404 in Combination With Different Anticancer Agents in Advanced 
 Cancers\nEstimated primary completion: 8 March 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07227298
URL:https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
